Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abpro HoldingsABPO +5.39%9 EV-to-EBITDA is -1.89 as of Jul. 29, 2026. GuruFocus rates ABPO with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 407 Biotechnology companies, Abpro Holdings ranks better than 99.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Abpro Holdings's enterprise value is $-3.35 Mil.
Abpro Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1.77 Mil. Therefore, Abpro Holdings's EV-to-EBITDA for today is -1.89.
The historical rank and industry rank for Abpro Holdings's EV-to-EBITDA or its related term are showing as below:
ABPO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.23 Med: -1.27 Max: -0.09
Current: -1.89
During the past 4 years, the highest EV-to-EBITDA of Abpro Holdings was -0.09. The lowest was -14.23. And the median was -1.27.
ABPO's EV-to-EBITDA is ranked better than 99.51% of 407
companies
in the Biotechnology industry
Industry Median: 11.7
vs ABPO: -1.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abpro Holdings's PE Ratio (TTM) for today is calculated as:
Abpro Holdings's share price for today is $0.20508.
Abpro Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Abpro Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABPO vs SCNI, RMTG, CLSDQ: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Abpro Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abpro Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abpro Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Abpro Holdings's EV-to-EBITDA falls into.
Abpro Holdings's current Enterprise Value is $-3.35 Mil.
Abpro Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abpro Holdings (ABPO) has a EV-to-EBITDA of -1.89 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Abpro Holdings. According to the industry distribution chart, Abpro Holdings ranks #2 out of 407 companies in the Biotechnology industry, placing it in the top 0.5%.
Is Abpro Holdings' EV-to-EBITDA too high?
Abpro Holdings' current EV-to-EBITDA is -1.89. Based on the distribution chart, Abpro Holdings ranks #2 out of 407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abpro Holdings has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Abpro Holdings' EV-to-EBITDA compare to SCNI and RMTG?
According to the Biotechnology industry distribution chart, Abpro Holdings ranks #2 out of 407 companies for EV-to-EBITDA. This places Abpro Holdings in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 11.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.70, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Abpro Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abpro Holdings's current EV-to-EBITDA is -1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abpro Holdings stock overvalued right now?
Abpro Holdings (ABPO) has a current EV-to-EBITDA of -1.89. The current EV-to-EBITDA is -1.89. Abpro Holdings' overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Abpro Holdings (ABPO), the current EV-to-EBITDA is -1.89 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. The company is focused on novel antibody constructs for immuno-oncology, ophthalmology, and infectious diseases. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, the company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
9GF Score
Get the complete analysis for ABPO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABPO has been successfully added to your 
